Utility of network integrity methods in therapeutic target identification

Frontiers in Genetics

Volumn 5, Issue FEB, 2014, Pages

  Peng, Qian ^a,b,c   Schork, Nicholas J ^a,b,c  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b SCRIPPS TRANSLATIONAL SCIENCE INSTITUTE   (United States)

^c J CRAIG VENTER INSTITUTE   (United States)

Author keywords

Cancer; Centrality; Drug targets; Gene expression; Network analysis; Pathway; Personalized treatment

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE;

ARTICLE; BREAST CANCER; CANCER CELL; CONTROLLED STUDY; DRUG TARGETING; EDGE BETWEENNESS; EIGENVECTOR CENTRALITY; GENE EXPRESSION; GENE MUTATION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; MEASUREMENT; MOLECULAR GENETICS; NEOPLASM; NODE BETWEENNESS; PHENOTYPE; PROTEIN PROTEIN INTERACTION; SPECTRAL GAP CENTRALITY; UPREGULATION;

EID: 84897742681     PISSN: None     EISSN: 16648021     Source Type: Journal    
DOI: 10.3389/fgene.2014.00012     Document Type: Article

References (75)

1. Abaan, O. D., Polley, E. C., Davis, S. R., Zhu, Y. J., Bilke, S., Walker, R. L., et al. (2013). The exomes of the nci-60 panel: a genomic resource for cancer biology and systems pharmacology. Cancer Res. 73, 4372-4382. doi: 10.1158/0008-5472.CAN-12-3342.
2. Ágoston, V., Csermely, P., and Pongor, S. (2005). Multiple weak hits confuse complex systems: a transcriptional regulatory network as an example. Phys. Rev. E 71:051909. doi: 10.1103/PhysRevE.71.051909.
3. Arkin, M. R., and Wells, J. A. (2004). Small-molecule inhibitors of protein-protein interactions: progressing towards the dream. Nat. Rev. Drug Discov. 3, 301-317. doi: 10.1038/nrd1343.
4. Arun, B., and Goss, P. (2004). The role of cox-2 inhibition in breast cancer treatment and prevention. Semin Oncol. 31(2 Suppl. 7), 22-29. doi: 10.1053/j.seminoncol.2004.03.042.
5. Barabási, A.-L., Gulbahce, N., and Loscalzo, J. (2011). Network medicine: a network-based approach to human disease. Nat. Rev. Genet. 12, 56-68. doi: 10.1038/nrg2918.
6. Bermudez, O., Pagès, G., and Gimond, C. (2010). The dual-specificity MAP kinase phosphatases: critical roles in development and cancer. Am. J. Physiol. Cell Physiol. 299, C189-C202. doi: 10.1152/ajpcell.00347.2009.
7. Bonacich, P. (1972). Factoring and weighting approaches to clique identification. J. Math. Sociol. 2, 113-120. doi: 10.1080/0022250X.1972.9989806.
8. Brown, J. R., and DuBois, R. N. (2005). Cox-2: a molecular target for colorectal cancer prevention. J. Clin. Oncol. 23, 2840-2855. doi: 10.1200/JCO.2005.09.051.
9. Chen, Z., Gibson, T. B., Robinson, F., Silvestro, L., Pearson, G., Xu, B.-E., et al. (2001). MAP kinases. Chem. Rev. 101, 2449-2476. doi: 10.1021/cr000241p.
10. Chung, F. R. (1997). Spectral Graph Theory, Vol. 92. Providence, RI: AMS Bookstore.
11. Citri, A., and Yarden, Y. (2006). EGF-ERBB signalling: towards the systems level. Nat. Rev. Mol. Cell. Biol. 7, 505-516. doi: 10.1038/nrm1962.
12. Dar, A. C., Das, T. K., Shokat, K. M., and Cagan, R. L. (2012). Chemical genetic discovery of targets and anti-targets for cancer polypharmacology. Nature 486, 80-84. doi: 10.1038/nature11127.
13. Dhillon, A. S., Hagan, S., Rath, O., and Kolch, W. (2007). MAP kinase signalling pathways in cancer. Oncogene 26, 3279-3290. doi: 10.1038/sj.onc.1210421.
14. Dogrusoz, U., Giral, E., Cetintas, A., Civril, A., and Demir, E. (2005). "A compound graph layout algorithm for biological pathways," in Graph Drawing, Vol. 3383 of Lecture Notes in Computer Science, (New York, NY: Springer Berlin Heidelberg), 442-447.
15. Feng, L., Wang, J.-T., Jin, H., Qian, K., and Geng, J.-G. (2011). Sh3kbp1-binding protein 1 prevents epidermal growth factor receptor degradation by the interruption of c-cbl-cin85 complex. Cell Biochem. Funct. 29, 589-596. doi: 10.1002/cbf.1792.
16. Ferrajoli, A., Faderl, S., Ravandi, F., and Estrov, Z. (2006). The JAK-STAT pathway: a therapeutic target in hematological malignancies. Curr. Cancer Drug Targets 6, 671-679. doi: 10.2174/156800906779010227.
17. Freeman, L. C. (1978/79). Centrality of social networks conceptual clarification. Soc. Netw. 1, 215-239. doi: 10.1016/0378-8733(78)90021-7.
18. Garay, J. P., and Park, B. H. (2012). Androgen receptor as a targeted therapy for breast cancer. Am. J. Cancer Res. 2, 434-445.
19. Gerald, D., Berra, E., Frapart, Y. M., Chan, D. A., Giaccia, A. J., Mansuy, D., et al. (2004). Jund reduces tumor angiogenesis by protecting cells from oxidative stress. Cell 118, 781-794. doi: 10.1016/j.cell.2004.08.025.
20. Goh, K.-I., Cusick, M. E., Valle, D., Childs, B., Vidal, M., and Barabási, A.-L. (2007). The human disease network. Proc. Natl. Acad. Sci. U.S.A. 104, 8685-8690. doi: 10.1073/pnas.0701361104.
21. Greeve, M., Allan, R., Harvey, J., and Bentel, J. (2004). Inhibition of mcf-7 breast cancer cell proliferation by 5alpha-dihydrotestosterone; a role for p21(cip1/waf1). J. Mol. Endocrinol. 32, 793-810. doi: 10.1677/jme.0.0320793.
22. Gu, Z., Liu, J., Cao, K., Zhang, J., and Wang, J. (2012). Centrality-based pathway enrichment: a systematic approach for finding significant pathways dominated by key genes. BMC Syst. Biol. 6:56. doi: 10.1186/1752-0509-6-56.
23. Gupta, R. A., and DuBois, R. N. (2001). Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat. Rev. Cancer 1, 11-21. doi: 10.1038/35094017.
24. Han, J.-D. J., Bertin, N., Hao, T., Goldberg, D. S., Berriz, G. F., Zhang, L. V., et al. (2004). Evidence for dynamically organized modularity in the yeast protein-protein interaction network. Nature 430, 88-93. doi: 10.1038/nature02555.
25. Hebenstreit, D., Fang, M., Gu, M., Charoensawan, V., van Oudenaarden, A., and Teichmann, S. A. (2011). Rna sequencing reveals two major classes of gene expression levels in metazoan cells. Mol. Syst. Biol. 7:497. doi: 10.1038/msb.2011.28.
26. Hide, T., Takezaki, T., Nakatani, Y., Nakamura, H., Kuratsu, J.-I., and Kondo, T. (2011). Combination of a ptgs2 inhibitor and an epidermal growth factor receptor-signaling inhibitor prevents tumorigenesis of oligodendrocyte lineage-derived glioma-initiating cells. Stem Cells 29, 590-599. doi: 10.1002/stem.618.
27. Hix, L. M., Karavitis, J., Khan, M. W., Shi, Y. H., Khazaie, K., and Zhang, M. (2013). Tumor stat1 transcription factor activity enhances breast tumor growth and immune suppression mediated by myeloid-derived suppressor cells. J. Biol. Chem. 288, 11676-11688. doi: 10.1074/jbc.M112.441402.
28. Holbro, T., and Hynes, N. E. (2004). Erbb receptors: directing key signaling networks throughout life. Annu. Rev. Pharmacol. Toxicol. 44, 195-217. doi: 10.1146/annurev.pharmtox.44.101802.121440.
29. Horvath, S. (2011). Weighted Network Analysis: Applications in Genomics and Systems Biology. New York, NY; Springer. doi: 10.1007/978-1-4419-8819-5.
30. Hughes, B. (2007). Cancer: multiple targets to tackle tough tumours. Nat. Rev. Drug Discov. 6, 867-867. doi: 10.1038/nrd2449.
31. Jeong, H., Mason, S. P., Barabasi, A. L., and Oltvai, Z. N. (2001). Lethality and centrality in protein networks. Nature 411, 41-42. doi: 10.1038/35075138.
32. Jiang, Z.-X., and Zhang, Z.-Y. (2008). Targeting PTPs with small molecule inhibitors in cancer treatment. Cancer Metast. Rev. 27, 263-272. doi: 10.1007/s10555-008-9113-3.
33. Jonsson, P. F., and Bates, P. A. (2006). Global topological features of cancer proteins in the human interactome. Bioinformatics 22, 2291-2297. doi: 10.1093/bioinformatics/btl390.
34. Kandasamy, K., Mohan, S. S., Raju, R., Keerthikumar, S., Kumar, G., Venugopal, A., et al. (2010). Netpath: a public resource of curated signal transduction pathways. Genome Biol. 11:R3. doi: 10.1186/gb-2010-11-1-r3.
35. Kanehisa, M., and Goto, S. (2000). KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 28, 27-30. doi: 10.1093/nar/28.1.27.
36. Kang, J. M., Park, S., Kim, S. J., Hong, H. Y., Jeong, J., Kim, H.-S., et al. (2012). Cbl enhances breast tumor formation by inhibiting tumor suppressive activity of tgf-Κ signaling. Oncogene 31, 5123-5131. doi: 10.1038/onc.2012.18.
37. Kang, Y., He, W., Tulley, S., Gupta, G. P., Serganova, I., Chen, C.-R., et al. (2005). Breast cancer bone metastasis mediated by the smad tumor suppressor pathway. Proc. Natl. Acad. Sci. U.S.A. 102, 13909-13914. doi: 10.1073/pnas.0506517102.
38. Katz, L. (1953). A new status index derived from sociometric analysis. Psychometrika 18, 39-43. doi: 10.1007/BF02289026.
39. Khodarev, N. N., Roizman, B., and Weichselbaum, R. R. (2012). Molecular pathways: interferon/stat1 pathway: Role in the tumor resistance to genotoxic stress and aggressive growth. Clin. Cancer Res. 18, 3015-3021. doi: 10.1158/1078-0432.CCR-11-3225.
40. Koschützki, D., and Schreiber, F. (2008). Centrality analysis methods for biological networks and their application to gene regulatory networks. Gene Regul. Syst. Bio. 2, 193-201.
41. Krupp, M., Marquardt, J. U., Sahin, U., Galle, P. R., Castle, J., and Teufel, A. (2012). RNA-Seq Atlas-a reference database for gene expression profiling in normal tissue by next-generation sequencing. Bioinformatics 28, 1184-1185. doi: 10.1093/bioinformatics/bts084.
42. Li, J., Kong, X., Zhang, J., Luo, Q., Li, X., and Fang, L. (2013). Mirna-26b inhibits proliferation by targeting ptgs2 in breast cancer. Cancer Cell Int. 13:7. doi: 10.1186/1475-2867-13-7.
43. Li, M., Wang, J., Chen, X., Wang, H., and Pan, Y. (2011). A local average connectivity-based method for identifying essential proteins from the network level. Comput. Biol. Chem. 35, 143-150. doi: 10.1016/j.compbiolchem.2011.04.002.
44. Lima-Mendez, G., and van Helden, J. (2009). The powerful law of the power law and other myths in network biology. Mol. BioSyst. 5, 1482-1493. doi: 10.1039/b908681a.
45. Macedo, L. F., Guo, Z., Tilghman, S. L., Sabnis, G. J., Qiu, Y., and Brodie, A. (2006). Role of androgens on mcf-7 breast cancer cell growth and on the inhibitory effect of letrozole. Cancer Res. 66, 7775-7782. doi: 10.1158/0008-5472.CAN-05-3984.
46. McCall, M. N., Uppal, K., Jaffee, H. A., Zilliox, M. J., and Irizarry, R. A. (2011). The gene expression barcode: leveraging public data repositories to begin cataloging the human and murine transcriptomes. Nucleic Acids Res. 39(Suppl. 1), D1011-D1015. doi: 10.1093/nar/gkq1259.
47. Mering, C. v., Huynen, M., Jaeggi, D., Schmidt, S., Bork, P., and Snel, B. (2003). STRING: a database of predicted functional associations between proteins. Nucleic Acids Res. 31, 258-261. doi: 10.1093/nar/gkg034.
48. Mesa, R. A. (2010). Ruxolitinib, a selective jak1 and jak2 inhibitor for the treatment of myeloproliferative neoplasms and psoriasis. IDrugs 13, 394-403.
49. Mortazavi, A., Williams, B. A., McCue, K., Schaeffer, L., and Wold, B. (2008). Mapping and quantifying mammalian transcriptomes by RNA-Seq. Nat. Meth. 5, 621-628. doi: 10.1038/nmeth.1226.
50. Nagaraj, N. S., and Datta, P. K. (2010). Targeting the transforming growth factor-beta signaling pathway in human cancer. Expert Opin. Invest. Drugs 19, 77-91. doi: 10.1517/13543780903382609.
51. Ogata, Y., Osaki, T., Naka, T., Iwahori, K., Furukawa, M., Nagatomo, I., et al. (2006). Overexpression of PIAS3 suppresses cell growth and restores the drug sensitivity of human lung cancer cells in association with PI3-K/Akt inactivation. Neoplasia 8, 817-825. doi: 10.1593/neo.06409.
52. Okamoto, T., Inozume, T., Mitsui, H., Kanzaki, M., Harada, K., Shibagaki, N., et al. (2010). Overexpression of grim-19 in cancer cells suppresses stat3-mediated signal transduction and cancer growth. Mol. Cancer Ther. 9, 2333-2343. doi: 10.1158/1535-7163.MCT-09-1147.
53. Page, L., Brin, S., Motwani, R., and Winograd, T. (1999). The Pagerank Citation Ranking: Bringing Order to the Web. Technical Report 1999-66, Stanford InfoLab.
54. Perumal, D., Lim, C. S., and Sakharkar, M. K. (2009). A comparative study of metabolic network topology between a pathogenic and a non-pathogenic bacterium for potential drug target identification. Summit. Trans. Bioinf. 2009, 100-104.
55. Petrelli, A., and Giordano, S. (2008). From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage. Curr. Med. Chem. 15, 422-432. doi: 10.2174/092986708783503212.
56. Pico, A. R., Kelder, T., van Iersel, M. P., Hanspers, K., Conklin, B. R., and Evelo, C. (2008). WikiPathways: pathway editing for the people. PLoS. Biol. 6:e184. doi: 10.1371/journal.pbio.0060184.
57. Pourdehnad, M., Truitt, M. L., Siddiqi, I. N., Ducker, G. S., Shokat, K. M., and Ruggero, D. (2013). Myc and mtor converge on a common node in protein synthesis control that confers synthetic lethality in myc-driven cancers. Proc. Natl. Acad. Sci. U.S.A. 110, 11988-11993. doi: 10.1073/Pnas.1310230110.
58. Ranola, J. M., Langfelder, P., Lange, K., and Horvath, S. (2013). Cluster and propensity based approximation of a network. BMC Syst. Biol. 7:21. doi: 10.1186/1752-0509-7-21.
59. Sabidussi, G. (1966). The centrality index of a graph. Psychometrika 31, 581-603. doi: 10.1007/BF02289527.
60. Sansone, P., and Bromberg, J. (2012). Targeting the interleukin-6/jak/stat pathway in human malignancies. J. Clin. Oncol. 30, 1005-1014. doi: 10.1200/JCO.2010.31.8907.
61. Scaltriti, M., and Baselga, J. (2006). The epidermal growth factor receptor pathway: a model for targeted therapy. Clin. Cancer Res. 12, 5268-5272. doi: 10.1158/1078-0432.CCR-05-1554.
62. Scherf, U., Ross, D. T., Waltham, M., Smith, L. H., Lee, J. K., Tanabe, L., et al. (2000). A gene expression database for the molecular pharmacology of cancer. Nat. Genet. 24, 236-244. doi: 10.1038/73439.
63. Soubeyran, P., Kowanetz, K., Szymkiewicz, I., Langdon, W. Y., and Dikic, I. (2002). Cbl-cin85-endophilin complex mediates ligand-induced downregulation of egf receptors. Nature 416, 183-187. doi: 10.1038/416183a.
64. Sun, J., and Zhao, Z. (2010). A comparative study of cancer proteins in the human protein-protein interaction network. BMC Genom. 11(Suppl. 3):S5. doi: 10.1186/1471-2164-11-S3-S5.
65. Valente, T. W., and Foreman, R. K. (1998). Integration and radiality: measuring the extent of an individual's connectedness and reachability in a network. Soc. Netw. 20, 89-105. doi: 10.1016/S0378-8733(97)00007-5.
66. Verstovsek, S., Mesa, R. A., Gotlib, J., Levy, R. S., Gupta, V., DiPersio, J. F., et al. (2012). A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. New Eng. J. Med. 366, 799-807. doi: 10.1056/NEJMoa1110557.
67. Wang, J., Chen, G., Li, M., and Pan, Y. (2011). Integration of breast cancer gene signatures based on graph centrality. BMC Syst. Biol. 5(Suppl. 3):S10. doi: 10.1186/1752-0509-5-S3-S10.
68. Wang, X., Thijssen, B., and Yu, H. (2013). Target essentiality and centrality characterize drug side effects. PLoS Comput. Biol. 9:e1003119. doi: 10.1371/journal.pcbi.1003119.
69. Wehmuth, K., and Ziviani, A. (2011). "Distributed location of the critical nodes to network robustness based on spectral analysis," in Network Operations and Management Symposium (LANOMS), 2011 7th Latin American (Quito), 1-8. doi: 10.1109/LANOMS.2011.6102259.
70. Xia, J., Sun, J., Jia, P., and Zhao, Z. (2011). Do cancer proteins really interact strongly in the human protein-protein interaction network? Comput. Biol. Chem. 35, 121-125. doi: 10.1016/j.compbiolchem.2011.04.005.
71. Xu, J., Chen, Y., and Olopade, O. I. (2010). Myc and breast cancer. Genes Cancer 1, 629-640. doi: 10.1177/1947601910378691.
72. Xu, S., Robbins, D., Frost, J., Dang, A., Lange-Carter, C., and Cobb, M. H. (1995). Mekk1 phosphorylates mek1 and mek2 but does not cause activation of mitogen-activated protein kinase. Proc. Natl. Acad. Sci. U.S.A. 92, 6808-6812. doi: 10.1073/pnas.92.15.6808.
73. Yang, S.-H., Sharrocks, A. D., and Whitmarsh, A. J. (2003). Transcriptional regulation by the MAP kinase signaling cascades. Gene 320, 3-21. doi: 10.1016/S0378-1119(03)00816-3.
74. Yu, H., Pardoll, D., and Jove, R. (2009). STATs in cancer inflammation and immunity: a leading role for STAT3. Nat. Rev. Cancer 9, 798-809. doi: 10.1038/nrc2734.
75. Zhong, Q., Simonis, N., Li, Q.-R., Charloteaux, B., Heuze, F., Klitgord, N., et al. (2009). Edgetic perturbation models of human inherited disorders. Mol. Syst. Biol. 5:321. doi: 10.1038/msb.2009.80.